Sayin Burak, Colak Turan, Tutal Emre, Sezer Siren
Department of Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey.
Int J Nephrol Renovasc Dis. 2013 May 29;6:95-9. doi: 10.2147/IJNRD.S42042. Print 2013.
For suitable patients with end-stage renal disease, kidney transplantation (KT) is the best renal replacement therapy, resulting in lower morbidity and mortality rates and improved quality of life. Preemptive kidney transplantation (PKT) is defined as transplantation performed before initiation of maintenance dialysis and reported to be associated with superior outcomes of graft and patient survival. In our study, we aimed to compare the 5-year outcomes of PKT and nonpreemptive kidney transplantation (NPKT) patients who received KT in our center, to define the differences according to complications, comorbidities, adverse effects, clinical symptoms, periodical laboratory parameters, rejection episodes, graft, and patient survival.
One hundred kidney transplantation (37 PKT, 63 NPKT) recipients were included in our study. All patients were evaluated for adverse effects, complications, comorbidities, clinical symptoms, monthly laboratory parameters, acute rejection episodes, graft, and patient survival.
Acute rejection episodes were found to be significantly correlated with graft loss in both groups (P = 0.02 and P = 0.01, respectively). Hypertension after transplantation was diagnosed by ambulatory blood pressure measurement in 74 of 100 patients. Twenty-five of 37 (67.6%) of Group 1 (PKT) recipients had hypertension while 54 of 63 (85.4%) of Group 2 (NPKT) had hypertension. The incidence of hypertension between two groups was statistically significant (P = 0.03), but this finding was not correlated to graft survival (P = 0.07). Some patients had serious infections, requiring hospitalization, and were treated immediately. Infection rates between the two groups were 10.8% for Group 1 patients and 31.7% for Group 2 patients and were statistically significant (P = 0.02). Infection, requiring hospitalization, was found to be statistically correlated to graft loss in only NPKT patients (P = 0.00).
While the comparison of PKT and graft and patient survival with NPKT is poorer than we expected, lower morbidity rates of hypertension and infection are similar with recent data. Avoidance of dialysis-associated comorbidities, diminished immune response, and cardiovascular complications are the main benefits of PKT.
对于合适的终末期肾病患者,肾移植(KT)是最佳的肾脏替代治疗方法,可降低发病率和死亡率,并改善生活质量。抢先肾移植(PKT)定义为在开始维持性透析之前进行的移植,据报道其与移植物和患者生存的更好结果相关。在我们的研究中,我们旨在比较在我们中心接受KT的PKT患者和非抢先肾移植(NPKT)患者的5年结局,以根据并发症、合并症、不良反应、临床症状、定期实验室参数、排斥反应、移植物和患者生存来确定差异。
我们的研究纳入了100例肾移植受者(37例PKT,63例NPKT)。对所有患者进行了不良反应、并发症、合并症、临床症状、每月实验室参数、急性排斥反应、移植物和患者生存情况的评估。
发现两组中急性排斥反应均与移植物丢失显著相关(分别为P = 0.02和P = 0.01)。100例患者中有74例通过动态血压测量诊断出移植后高血压。第1组(PKT)的37例受者中有25例(67.6%)患有高血压,而第2组(NPKT)的63例中有54例(85.4%)患有高血压。两组之间高血压的发生率具有统计学意义(P = 0.03),但这一发现与移植物存活无关(P = 0.07)。一些患者发生了严重感染,需要住院治疗,并立即接受了治疗。第1组患者的感染率为10.8%,第2组患者为31.7%,具有统计学意义(P = 0.02)。仅在NPKT患者中发现需要住院治疗的感染与移植物丢失具有统计学相关性(P = 0.00)。
虽然PKT与NPKT在移植物和患者生存方面的比较比我们预期的要差,但高血压和感染的较低发病率与近期数据相似。避免透析相关的合并症、减少免疫反应和心血管并发症是PKT的主要益处。